- Home
- OMH vs BIAF Comparison
OMH vs BIAF Comparison
Compare OMH & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMH
- BIAF
- Stock Information
- Founded
- OMH 2015
- BIAF 2014
- Country
- OMH Singapore
- BIAF United States
- Employees
- OMH N/A
- BIAF N/A
- Industry
- OMH Real Estate
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- OMH Finance
- BIAF Health Care
- Exchange
- OMH Nasdaq
- BIAF Nasdaq
- Market Cap
- OMH 13.6M
- BIAF 12.2M
- IPO Year
- OMH 2023
- BIAF 2022
- Fundamental
- Price
- OMH $1.52
- BIAF $0.30
- Analyst Decision
- OMH Hold
- BIAF Hold
- Analyst Count
- OMH 1
- BIAF 1
- Target Price
- OMH N/A
- BIAF N/A
- AVG Volume (30 Days)
- OMH 5.4M
- BIAF 11.2M
- Earning Date
- OMH 07-07-2025
- BIAF 08-13-2025
- Dividend Yield
- OMH N/A
- BIAF N/A
- EPS Growth
- OMH N/A
- BIAF N/A
- EPS
- OMH N/A
- BIAF N/A
- Revenue
- OMH $7,976,578.00
- BIAF $8,809,228.00
- Revenue This Year
- OMH $28.40
- BIAF N/A
- Revenue Next Year
- OMH $23.07
- BIAF $20.00
- P/E Ratio
- OMH N/A
- BIAF N/A
- Revenue Growth
- OMH 117.53
- BIAF 78.40
- 52 Week Low
- OMH $0.59
- BIAF $0.16
- 52 Week High
- OMH $6.20
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- OMH 46.11
- BIAF 50.96
- Support Level
- OMH $1.45
- BIAF $0.22
- Resistance Level
- OMH $1.59
- BIAF $0.46
- Average True Range (ATR)
- OMH 0.40
- BIAF 0.04
- MACD
- OMH 0.02
- BIAF 0.01
- Stochastic Oscillator
- OMH 35.76
- BIAF 30.51
About OMH Ohmyhome Limited
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.